GleamWall
中文EN

OCGN Ocugen, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1372299 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-1.3%
TTM net income YoY-24.7%
TTM EPS YoY-11.2%
Revenue 3-yr CAGR22.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,483.9%
Net margin-1,605.2%
FCF margin-1,334.3%
EBITDA margin-1,430.1%

Returns

ROE-660.0%
ROA-118.1%
ROIC (approx.)-1,221.1%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets89.8%
Debt / equity5.03x
Current ratio1.86x
Interest coverage-12.62x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-20.2%
Payout ratio—
Capex / revenue3.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$4.41M$4.05M
R&D expense$39.75M$32.13M
SG&A expense$27.58M$26.69M
Operating income-$62.92M-$54.76M
Interest expense$5.19M$688,000
Pretax income-$67.85M-$54.05M
Income tax$0$0
Net income-$67.85M-$54.05M
EBITDA-$60.52M-$52.86M
EPS (diluted)——
Balance sheet
Cash & equivalents$18.57M$58.82M
Short-term investments$0—
Current assets$24.34M$61.68M
PP&E, net$14.39M$16.55M
Total assets$43.52M$82.44M
Current liabilities$23.04M$21.59M
Short-term debt$1.25M$1.33M
Long-term debt$27.54M$27.34M
Total debt$28.79M$28.67M
Total liabilities$55.68M$52.81M
Shareholders' equity-$12.17M$29.63M
Net debt$10.22M-$30.15M
Shares outstanding312.38M291.37M
Cash flow statement
Operating cash flow-$56.96M-$42.14M
Capital expenditure$185,000$3.38M
Free cash flow-$57.15M-$45.53M
Investing cash flow-$311,000-$3.38M
Financing cash flow$17.33M$64.86M
Depreciation & amortization$2.40M$1.90M
Stock-based compensation$7.71M$7.43M

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.